News.

Stay up to date with Aerpio.

News

5/16/17 - Aerpio Reports First Quarter 2017 Financial Results

Read the press release.

3/29/17 - Aerpio Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

Read the press release.

3/16/17 - Aerpio Pharmaceuticals Raises $40 Million

Read the press release.

3/8/17 - Aerpio Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

Read the press release.

6/13/16 - Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

Read the press release.

11/17/15 - Aerpio Therapeutics Reports Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

Read the press release.

10/9/15 - Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

Read the press release.

10/7/15 - Aerpio Appoints Steve Pakola, M.D. as Chief Medical Officer

Read the press release.

7/15/15 - Aerpio Therapeutics Announces Positive Results of a Phase 2a Study of AKB-9778 in Diabetic Macular Edema: The TIME-2 Trial

Read the press release.

4/9/15 - Aerpio Therapeutics to Present at the 14th Annual Needham Healthcare Conference

Read the press release.

3/4/15 - Aerpio Therapeutics Announces Publication of Positive Results of Phase 1b/2a Clinical Trial of Novel Tie2 Activator, AKB-9778, for the Treatment of Patients with Diabetic Macular Edema (DME) - TIME-1 Study

Read the press release.

12/4/14 - Aerpio Therapeutics Completes Enrollment of Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Patients with Diabetic Macular Edema

Read the press release.

9/2/14 - Aerpio Therapeutics Announces Publication of Preclinical Data on AKB-9778 for Common Eye Diseases

Read the press release.

5/5/14 - Aerpio Therapeutics Presents Full Results from Phase 1b/2a Study of AKB-9778

Read the press release.

4/23/14 - Aerpio Therapeutics Closes $22M Financing

Read the press release.

4/7/14 - Aerpio Therapeutics to Present at Needham Healthcare Conference

Read the press release.

2/13/14 - Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema

Read the press release.

11/6/13 - Aerpio Therapeutics Announces Successful Completion of Phase 1b/2a Trial in Diabetic Macular Edema and $9 Million Series A Extension

Read the press release.

8/5/13 - Aerpio Therapeutics Announces Publication of Data on Tie2 Activator, AKB-9778, Supporting Future Clinical Development in Cancer

Read the press release.

9/21/12 - Aerpio Therapeutics is proud to be an event sponsor for the upcoming 2012 annual NAVBO meeting.

Read the press release.

9/19/12 - Aerpio Therapeutics Initiates Phase 1b/2a Trial of AKB-9778 in Diabetic Macular Edema

Read the press release.

8/30/12 - Aerpio Therapeutics Completes $27 Million Series A Financing

Read the press release.

8/22/12 - Aerpio Therapeutics Hosts Scientific Symposium on Tie2 Pathway

Read the press release.

5/10/12 - Aerpio Appoints Dr. Adrienne Graves to Board of Directors

Read the press release.

3/20/12 - Aerpio Announces Positive Phase 1 Data on First-in-class Tie2 Activator, AKB-9778, in Development for Diabetic Macular Edema

Read the press release.

1/9/12 - New Company, Aerpio Therapeutics, Created to Advance Novel Tie-2 Activators and HIF-1α Stabilizers for Multiple Diseases

Read the press release.